Myriad Genetics, Inc. (MYGN)
Largest Insider Buys in Sector
MYGN Stock Price History Chart
MYGN Stock Performance
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic …
Insider Activity of Myriad Genetics, Inc.
Over the last 12 months, insiders at Myriad Genetics, Inc. have bought $0 and sold $9.51M worth of Myriad Genetics, Inc. stock.
On average, over the past 5 years, insiders at Myriad Genetics, Inc. have bought $563,557 and sold $7.21M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $498,672 was made by Phanstiel S. Louise (director) on 2020‑11‑11.
List of Insider Buy and Sell Transactions, Myriad Genetics, Inc.
| 2024-10-11 | Sale | President and CEO | 15,000 0.0144% | $22.93 | $343,950 | -5.44% | ||
| 2024-09-11 | Sale | President and CEO | 15,000 0.0163% | $26.72 | $400,800 | -1.24% | ||
| 2024-09-11 | Sale | Chief Scientific Officer | 2,100 0.0022% | $26.17 | $54,961 | +0.83% | ||
| 2024-09-09 | Sale | director | 10,000 0.011% | $27.05 | $270,520 | -3.68% | ||
| 2024-09-03 | Sale | director | 46,012 0.0516% | $27.95 | $1.29M | -3.90% | ||
| 2024-08-21 | Sale | SVP, Chief of Staff | 11,538 0.0127% | $27.82 | $320,987 | -3.58% | ||
| 2024-08-19 | Sale | director | 7,500 0.0082% | $28.01 | $210,075 | -4.60% | ||
| 2024-06-04 | Sale | director | 3,788 0.0041% | $22.05 | $83,525 | +18.49% | ||
| 2024-06-03 | Sale | director | 3,788 0.0041% | $22.04 | $83,488 | +18.31% | ||
| 2024-05-15 | Sale | President and CEO | 75,000 0.0843% | $25.07 | $1.88M | +5.27% | ||
| 2024-05-14 | Sale | President and CEO | 95,000 0.1043% | $25.21 | $2.39M | +2.37% | ||
| 2024-05-13 | Sale | President and CEO | 57,844 0.0644% | $25.13 | $1.45M | +3.89% | ||
| 2024-05-13 | Sale | director | 6,200 0.007% | $25.30 | $156,860 | +3.89% | ||
| 2023-12-01 | Sale | Chief Financial Officer | 30,000 0.0333% | $19.09 | $572,835 | +17.52% | ||
| 2023-11-01 | Sale | Chief Financial Officer | 30,000 0.0363% | $15.69 | $470,622 | +41.30% | ||
| 2023-06-02 | Sale | director | 8,638 0.0104% | $23.01 | $198,760 | -13.70% | ||
| 2023-03-27 | Sale | Chief Operating Officer | 6,433 0.008% | $23.48 | $151,047 | -11.11% | ||
| 2023-03-02 | Sale | Chief Financial Officer | 15,000 0.0182% | $22.55 | $338,253 | -9.52% | ||
| 2023-03-02 | Sale | Chief Operating Officer | 13,184 0.0161% | $22.74 | $299,823 | -9.52% | ||
| 2023-01-20 | Sale | Chief Financial Officer | 9,400 0.0114% | $20.04 | $188,386 | -4.86% |
Insider Historical Profitability
| Capone Mark Christopher | President & C.E.O. | 440833 0.4854% | $17.63 | 1 | 16 | <0.0001% |
| McDade Ralph L | President Myriad RBM, Inc. | 122604 0.135% | $17.63 | 1 | 1 | <0.0001% |
| HENDERSON JOHN T | director | 64353 0.0709% | $17.63 | 5 | 9 | +11.11% |
| Phanstiel S. Louise | director | 61646 0.0679% | $17.63 | 1 | 2 | +79.17% |
| GILBERT WALTER PHD | director | 54150 0.0596% | $17.63 | 1 | 16 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $317.23M | 16.44 | 14.88M | +1.51% | +$4.71M | 0.01 | |
| The Vanguard Group | $213.96M | 11.09 | 10.04M | +0.82% | +$1.74M | <0.01 | |
| Wellington Management Company | $171.84M | 8.9 | 8.06M | +11.64% | +$17.92M | 0.03 | |
| Camber Capital Management Lp | $162.78M | 8.44 | 7.63M | 0% | +$0 | 5.74 | |
| State Street | $115.21M | 5.97 | 5.4M | +14.96% | +$14.99M | 0.01 |